Myriad Genetics Inc

MYGN

Add to Watchlist

3.764USD

-0.305-7.51%

Market hours （ET）Quotes delayed by 15 min

Myriad Genetics Inc's Score

Industry at a Glance

Industry Ranking

86 / 206

Overall Ranking

203 / 4490

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Myriad Genetics Inc Highlights

StrengthsRisks

Myriad Genetics, Inc. is a genetic testing and precision medicine company. The Company develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. The Company is focused on three key areas where it has specialized products, capabilities, and expertise: Oncology, Women's Health, and Mental Health. In oncology, it offers testing for patients who have cancer and companion diagnostic tests that work with corresponding drugs and treatments. It also offers the SneakPeek Early Gender DNA Test, which can reveal a baby's gender as early as six weeks into pregnancy. The Company’s testing products include MyRisk, BRACAnalysis, BRACAnalysis CDx, MyChoice CDx, Prolaris, Foresight, Prequel, Precis Tumor, Precise Liquid, SneakPeek and GeneSight, among others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 824.50M.

Overvalued

The company’s latest PE is -0.94, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 102.95M shares, decreasing 6.61% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 2.33K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of 0.10.

Analyst Rating

Based on 11 analysts

Hold

Current Rating

6.222

Target Price

+45.04%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Myriad Genetics Inc is 6.67, ranking 128 out of 206 in the Healthcare Equipment & Supplies industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 200.40M, representing a year-over-year increase of 2.30%, while its net profit experienced a year-over-year increase of 34000.00%.

Score

Industry at a Glance

Previous score

6.67

Change

0



Financials

8.24

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

5.22

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.11

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.63

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.13

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Myriad Genetics Inc is 7.90, ranking 53 out of 206 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.94, which is -5.44% below the recent high of -0.89 and -2181.40% above the recent low of -21.52.

Score

Industry at a Glance

Previous score

7.90

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 86/206

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Myriad Genetics Inc is 5.82, ranking 185 out of 206 in the Healthcare Equipment & Supplies industry. The average price target is 8.00, with a high of 18.00 and a low of 3.50.

Score

Industry at a Glance

Previous score

5.85

Change

-0.03

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Myriad Genetics Inc is 6.47, ranking 140 out of 206 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 5.04 and the support level at 3.43, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.52

Change

-0.05

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Myriad Genetics Inc is 10.00, ranking 1 out of 206 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 109.00%, representing a quarter-over-quarter increase of 9.24%. The largest institutional shareholder is Larry Robbins, holding a total of 4.94M shares, representing 5.23% of shares outstanding, with 23.66% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

13.66M

+3.09%

Millennium Management LLC

6.70M

+41.11%

State Street Investment Management (US)

5.97M

+19.90%

Glenview Capital Management, LLC

Star Investors

4.94M

+7.71%

D. E. Shaw & Co., L.P.

4.51M

-1.18%

Morgan Stanley & Co. LLC

2.92M

+17.08%

Jacobs Levy Equity Management, Inc.

2.27M

-7.06%

Geode Capital Management, L.L.C.

2.23M

+0.28%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Myriad Genetics Inc is 4.82, ranking 95 out of 206 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.79. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Myriad Genetics Inc

MYGN

6.79 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Lantheus Holdings Inc

LNTH

8.76 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Anika Therapeutics Inc

ANIK

8.57 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

LivaNova PLC

LIVN

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Thermo Fisher Scientific Inc

TMO

8.39 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Bruker Corp

BRKR

8.30 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment